The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2

FBXW2 作为一种新型肺肿瘤抑制因子与致癌 β-TrCP 和 SKP2 相互作用的作用

基本信息

  • 批准号:
    10017668
  • 负责人:
  • 金额:
    $ 36.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-11 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): SCF (SKP1-Cullins-F box protein) E3 ubiquitin ligase is the largest family of E3 ligases that promote the ubiquitylation and degradation of various key regulatory proteins, thus controlling many important biological processes, such as apoptosis, cell cycle progression, DNA replication, embryogenesis and tumorigenesis. SCF consists of 4 components, including a scaffold protein cullin-1, an adaptor protein SKP1, a RING protein RBX1 or RBX2 and an F-box protein. The F-box protein with 69 members in mammalian cells is the substrate- recognizing subunit that determines the specificity of SCF E3s. While a variety of protein substrates have been identified by one of well-characterized F-box proteins ßTrCP, FBXW7, or SKP2, very little is known as to whether and how F-box proteins regulate each other. Our preliminary data showed that 1) oncogenic F-box protein TrCP binds to yet a poorly characterized F-box protein FBXW2 to promote its ubiquitylation and degradation; 2) FBXW2 in turn binds to oncogenic F-box protein SKP2 to promote its ubiquitylation and degradation; 3) FBXW2 has tumor suppressive function against lung cancer cells; 4) A number of gain-of- function FBXW2 mutations were found in human non-small cell lung carcinoma tissues; and 5) reversed correlation in expression among β-TrCP, FBXW2 and SKP2 exists in lung cancer tissues, which is associated with patient survival. Although β-TrCP and SKP2 are well-studied F-box proteins with oncogenic activity, whether and how they regulate each other with regard to cell proliferation and survival is totally unknown. The objectives of this proposed study is to understand how FBXW2 mediates and modulates the activity of two well-known oncogenic F-box proteins, β-TrCP and SKP2, and how FBXW2 acts as a novel tumor suppressor in lung tumorigenesis using both in vitro cell culture and in vivo genetically modified mouse models with elucidation of its mechanism of action. The central hypothesis is that three F- box proteins, βTrCP-FBXW2-SKP2 form an oncogene-tumor suppressor-oncogene axis that regulates each other to control cell proliferation and lung tumorigenesis. Three specific aims are proposed to test our central hypothesis by 1) characterizing FBXW2 as a novel substrate of β-TRCP; 2) characterizing FBXW2 as a novel E3 ligase for SKP2 degradation; and 3) characterizing Fbxw2 as a novel tumor suppressor against lung tumorigenesis. Relevance: Successful completion of this proposed study will mechanistically elucidate how three F-box proteins regulate proliferation of lung cancer cells by targeting each other for degradation, and how two oncogenic F-box proteins ß-TrCP and SKP2 talk with each other via a tumor suppressive F-box protein FBXW2, and how FBXW2 acts as a tumor suppressor in the lung, thus elucidating a novel mechanism of lung tumorigenesis and providing attractive targets for future biomarker development in lung cancer management.
描述(由应用提供):SCF(SKP1碳蛋白-F盒蛋白)E3泛素连接酶是E3连接酶的最大家族,可促进各种关键调节蛋白的泛素化和降解,从而控制许多重要的生物学过程,例如凋亡,细胞周期进展,DNA重复,embryation,Embryegen和Tumorige剂。 SCF由4个成分组成,包括脚手架蛋白Cullin-1,衔接蛋白SKP1,环蛋白RBX1或RBX2和F-box蛋白。哺乳动物细胞中有69个成员的F-box蛋白是确定SCF E3特异性的亚基的底物。尽管特征良好的F-box蛋白β,FBXW7或SKP2鉴定了多种蛋白质底物,但对于F-box蛋白是否以及如何相互调节,很少知道。我们的初步数据显示4)在人类非小细胞肺癌组织中发现了许多功能FBXW2突变。 5)在肺癌组织中存在β-TRCP,FBXW2和SKP2之间表达的相关性,这与患者的生存有关。尽管β-TRCP和SKP2是具有致癌活性的经过良好研究的F-box蛋白,但它们是否以及如何相互调节在细胞增殖和生存方面是完全未知的。这项拟议的研究的目标是了解FBXW2如何介导并调节两种众所周知的致癌F-box蛋白β-trcp和​​SKP2的活性,以及​​FBXW2如何在肺部肿瘤中使用遗传培养物和遗传模型的模型在肺部肿瘤中起新型肿瘤抑制作用。中心假设是三个F-box蛋白β-TRCP-FBXW2-SKP2形成了一种肿瘤 - 抑制抑制剂 - 依符轴,它们相互调节以控制细胞增殖,并提出了三个特定目标,以表征我们的中心假设,以1)表征FBXW2作为新型substrateβ-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-β-蛋白酶; 2)将fbxw2表征为新型的E3连接酶,用于SKP2降解; 3)将FBXW2表征为一种针对肺肿瘤发生的新型肿瘤抑制。 Relevance: Successful completion of this proposed study will mechanistically elucidate how three F-box proteins regulate proliferation of lung Cancer cells by targeting each other for degradation, and how two oncogenic F-box proteins ß-TrCP and SKP2 talk with each other via a tumor suppressive F-box protein FBXW2, and how FBXW2 acts as a tumor suppressor in the lung, thus elucidating a肺肿瘤发生的新型机制,为肺癌管理中未来生物标志物的发展提供了有吸引力的靶标。

项目成果

期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
  • DOI:
    10.1158/1541-7786.mcr-21-0219
  • 发表时间:
    2021-09
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Zhao K;Zhang Q;Flanagan SA;Lang X;Jiang L;Parsels LA;Parsels JD;Zou W;Lawrence TS;Buisson R;Green MD;Morgan MA
  • 通讯作者:
    Morgan MA
Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2.
  • DOI:
    10.18632/oncotarget.740
  • 发表时间:
    2012-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wang Z;Inuzuka H;Zhong J;Liu P;Sarkar FH;Sun Y;Wei W
  • 通讯作者:
    Wei W
SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S E2s to ubiquitylate β-TrCP1 via K11-linkage for degradation.
SAG/RBX2 E3 连接酶与 UBCH10 和 UBE2S E2 复合物通过 K11 连接泛素化 β-TrCP1 进行降解。
  • DOI:
    10.1038/srep37441
  • 发表时间:
    2016-12-02
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Kuang P;Tan M;Zhou W;Zhang Q;Sun Y
  • 通讯作者:
    Sun Y
Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid.
  • DOI:
    10.1371/journal.pone.0027726
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Tan M;Li Y;Yang R;Xi N;Sun Y
  • 通讯作者:
    Sun Y
Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.
  • DOI:
    10.1038/cddis.2012.125
  • 发表时间:
    2012-09-06
  • 期刊:
  • 影响因子:
    9
  • 作者:
    Zhao, Y.;Xiong, X.;Jia, L.;Sun, Y.
  • 通讯作者:
    Sun, Y.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Meredith A Morgan其他文献

Meredith A Morgan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Meredith A Morgan', 18)}}的其他基金

Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy
项目 1:将 PARP 抑制与放射治疗相结合,使 HR 熟练的胰腺癌对免疫治疗敏感
  • 批准号:
    10554472
  • 财政年份:
    2023
  • 资助金额:
    $ 36.81万
  • 项目类别:
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer
靶向 DNA 损伤反应并结合放射诱导先天免疫并提高胰腺癌免疫治疗效果
  • 批准号:
    10352416
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer
靶向 DNA 损伤反应并结合放射诱导先天免疫并提高胰腺癌免疫治疗效果
  • 批准号:
    10574566
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
胰腺癌对 Chk1 和 PARP1 抑制疗法的选择性增敏
  • 批准号:
    8527743
  • 财政年份:
    2012
  • 资助金额:
    $ 36.81万
  • 项目类别:
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
胰腺癌对 Chk1 和 PARP1 抑制疗法的选择性增敏
  • 批准号:
    8372495
  • 财政年份:
    2012
  • 资助金额:
    $ 36.81万
  • 项目类别:
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
胰腺癌对 Chk1 和 PARP1 抑制疗法的选择性增敏
  • 批准号:
    9096053
  • 财政年份:
    2012
  • 资助金额:
    $ 36.81万
  • 项目类别:
Experimental Irradiation (EI)
实验辐射(EI)
  • 批准号:
    10627267
  • 财政年份:
    1997
  • 资助金额:
    $ 36.81万
  • 项目类别:

相似国自然基金

草鱼贮藏过程肌细胞凋亡对鱼肉品质的影响机制研究
  • 批准号:
    32372397
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
VNN1通过内质网非折叠蛋白应激介导单核巨噬细胞凋亡影响创伤患者脓毒症发生的机制研究
  • 批准号:
    82372549
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
MLCK1介导细胞凋亡和自噬影响炎症性肠病进展
  • 批准号:
    82370568
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
EHMT1通过CBX4/MLKL轴调控心肌细胞坏死性凋亡影响心肌缺血再灌注损伤的机制研究
  • 批准号:
    82370288
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
应激颗粒自噬对低氧诱导猪卵泡颗粒细胞凋亡的影响及机制研究
  • 批准号:
    32302741
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of NLRP3 inhibitors for HIV-associated neuroinflammation
开发治疗 HIV 相关神经炎症的 NLRP3 抑制剂
  • 批准号:
    10548568
  • 财政年份:
    2022
  • 资助金额:
    $ 36.81万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10688086
  • 财政年份:
    2022
  • 资助金额:
    $ 36.81万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10525097
  • 财政年份:
    2022
  • 资助金额:
    $ 36.81万
  • 项目类别:
Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
Caspase-8-N4BP1 轴对促炎细胞因子反应的调节
  • 批准号:
    10704065
  • 财政年份:
    2022
  • 资助金额:
    $ 36.81万
  • 项目类别:
Tspan14 expression and function in cardiovascular disease
Tspan14在心血管疾病中的表达和功能
  • 批准号:
    10656419
  • 财政年份:
    2022
  • 资助金额:
    $ 36.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了